Clinical Trial Update: Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [Phase 3]

View source ↗

Summary

Phase 3 extension study evaluating maintenance subcutaneous immunoglobulin (IgPro20) in CIDP has been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy
• Polyradiculoneuropathy Chronic Inflammatory Demyelinating

Drugs mentioned

• IgPro20 (intravenous immunoglobulin 20% solution)

Snippet

Sponsor: CSL Behring | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 3 | Status: COMPLETED | Results posted: 2018-10-02